期刊文献+

Ⅰ期≤20 mm微小结节肺腺癌患者术后长期生存分析 被引量:3

Analysis of long-term survival of resected stage Ⅰ lung adenocarcinoma with less then 20 mm micro-small pulmonary nodules
原文传递
导出
摘要 目的:回顾性分析手术切除的直径≤20 mm的Ⅰ期微小结节肺腺癌患者的5年生存率,以及5年生存率与患者临床特征、影像学特点和干预方法间的关系。方法:收集2007年6月—2015年5月就诊的404例有高分辨CT(high resolutionCT,HRCT)图像、直径≤20mm、手术切除肺微小结节的肺癌患者进行研究。其中311例为Ⅰ期肺腺癌,直径≤10 mm的微结节患者102例,直径为11~20mm的小结节患者209例。分析患者的5年生存率与影像特点、临床特征和治疗方法的关系。结果:微小结节肺腺癌患者的5年生存率为97.7%,微结节和小结节肺腺癌患者的5年生存率分别为99.0%和97.2%。女性微小结节肺腺癌患者的5年生存率明显高于男性(98.4%vs 96.4%,P=0.042),吸烟微小结节肺腺癌患者的5年生存率低于不吸烟患者(92.3%vs 98.5%,P=0.019)。肺腺癌病理亚型、手术范围、有无淋巴结清扫和是否胸腔镜手术与患者的5年生存率无明显关系(P值均> 0.05)。结论:直径≤20 mm的Ⅰ期微小结节肺腺癌患者预后良好,男性和吸烟可能增加了患者的死亡风险。 Objective: To retrospectively study the 5-year survival rate of stage I lung adenocarcinoma patients with resected micro- and small- sized pulmonary nodules, and its relationship with the clinical characteristics, imaging features and intervention methods. Methods: From Jun 2007 to May 2015, a total of 404 cases with pulmonary nodules in diameter ≤20 mm detected by high resolution computed tomography (HRCT) and received surgical resection were enrolled. Among them, 311 cases had stage I lung adenocarcinoma,102 cases had micro-sized (diameter ≤10 mm) pulmonary nodules, 209 cases had small- sized (11 - 20 ram) pulmonary nodules. The relationship of 5-year survival with the clinical characteristics, imaging features and intervention methods was analyzed. Results: The 5-year survival rate of adenocarcinoma patients was 97.7%, and which of patients with micro- and small-sized pulmonary nodules was 99.0% and 97.2%, respectively. The 5-year survival rate of female patients with micro- and small-sized pulmonary nodules was higher than that of male patients (98.4% vs 96.4%, P = 0.042). The 5-year survival rate of smokers was lower than that of non-smokers (92.3% vs 98.5%, P = 0.019). The pathological subtypes, surgical range, lymph node dissection, and thoracoscopic surgery were not associated with 5-year survival rate (all P 〉 0.05). Conclusion: The stage I lung adenocarcinoma patients with micro- and small-sized (diameter 20 ram) pulmonary nodules have a good prognosis. For these patients, male and smoking may increase the risk of death.
作者 简红 王章权 顾琳萍 罗清泉 陈群慧 叶剑定 张杰 赵晓菁 廖美琳 JIAN Hong;WANG Zhangquan;GU Linping;LUO Qingquan;CHEN Qunhui;YE Jianding;ZHANG Jie;ZHAO Xiaojing;LIAO Meilin(Department of Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Radiology,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Pathology,Shanghai Chest Hospital,Shanghai Jian Tong University,Shanghai 200030,China;Department of Thoracic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200240,China)
出处 《肿瘤》 CAS CSCD 北大核心 2018年第11期1048-1054,1070,共8页 Tumor
基金 上海市卫生和计划生育委员会科研课题(编号:201440330)~~
关键词 肺肿瘤 腺癌 微小肺结节 预后 Lung neoplasms Adenocarcinoma Micro and small-sized pulmonary nodules Prognosis
  • 相关文献

参考文献3

二级参考文献27

  • 1Cancer Genome Altas Research Network.Comprehensive molecular profiling of lung adenocarcinoma[J].Nature,2014,511(7511):543-550.
  • 2Kim HS,Mitsudomi T,Soo RA,et al.Personalized therapy on the horizon for squamous ceil carcinoma of the lung[J].Lung Cancer,2013,80(3):249-255.
  • 3Ettinger DS,Wood DE, Akerley W, et al.NCCN Guidelines insights:Non-small cell lung cancer,Version 4.2016[J]. J Natl Compr Canc Netw,2016,14(3):255-264.
  • 4Li J,Li X,Ren S1 et al.miR-200c overexpression is associated with better efficacy of ECFR-TKIs in non- small cell lung cancer patients with ECFR wild-type[J]. Oncotarget,2014,5(17):7902-7916.
  • 5Ren S1 Su C,Wang Z1 et al.Epithelial phenotype as predictive marker for response to ECFR-TKIs in non-small cell lung cancer patients with wild- type ECFR[J]. Int J Cancer,2014,135(12):2962-2971.
  • 6Cheng N,Cai W,Ren S,et al.Long non-coding RNA UCAl induces non- T790M acquired resistance to EGFR- TKIs by activating the AKT/mTOR pathway in ?C7F/?-mutant non-small cell lung cancer[J].Oncotarget,2015,6(27):23582-23593.
  • 7Cai W,Li X,Su C1 et al.ROS\ fusions in Chinese patients with non-small- cell lung cancer[J].Ann Oncol,2013,24(7):1822-1827.
  • 8Cai W,Su C,Li X,et al.K/FSB-RET fusions in Chinese patients with non- small cell lung cancer[J].Cancer,2013,119(8):1486-1494.
  • 9Doebele RC1 Pilling AB,Aisner DL,et al.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer[J].Clin Cancer Res,2012,18(5):1472-1482.
  • 10Gettinger SN,Bazhenova L,Salgia R,et al.Updated efficacy and safety of the ALK inhibitor AP26113 in patients(pts)with advanced malignancies,including ALK+ non-small cell lung cancer(NSCLC)[J].7 Clin Oncol,2014,32(suppl 5):abstr 8047.

共引文献766

同被引文献25

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部